Evonik stock at EUR 21.39, up 1.28% premarket
Published on 11/09/2026 at 07:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Evonik increased third-quarter adjusted EBITDA by 40 percent year on year to EUR 629 million.
- Management expects full-year 2026 adjusted EBITDA in the upper half of the EUR 2.0 billion to EUR 2.2 billion range.
- The company expects fourth-quarter earnings to exceed the prior-year level.
Evonik stock traded at EUR 21.39 on Lang & Schwarz at 07:41 CET on Monday, November 9, 2026, 1.28 percent above the Xetra close of Friday, November 6.
Evonik reported adjusted EBITDA of EUR 629 million for the third quarter on November 3, up 40 percent from the prior-year period. The specialty chemicals group said its 2026 adjusted EBITDA is likely to land in the upper half of the EUR 2.0 billion to EUR 2.2 billion range. It also expects fourth-quarter earnings to exceed the prior-year level.
The company said third-quarter sales rose 13 percent year on year and free cash flow reached EUR 369 million. A EUR 313 million provision for the extended efficiency program weighed on net income, which remained negative at EUR 53 million.
Outlook remains the focus
The stronger operating outlook gives investors a clearer earnings reference after a volatile period for the chemical sector. Evonik is also targeting a return on capital employed of more than 8 percent in 2026, compared with 6.1 percent in 2025, according to its third-quarter release.
For continuous price tracking, use the real-time quote of Evonik stock.
European investors are also watching the DAX, the benchmark for the German market.
